The French Competition Authority announced its approval for a pending merger between pharmaceutical giants Actavis and Warner Chilcott, say reports. Actavis’s buyout of Warner Chilcott remains pending. The German Federal Cartel Office has similarly cleared the deal and, according to a press release, the parties have now obtained permission from all ex-US antitrust regulators. Financial details of the deal were not made public. Actavis, based in the US, recently went head-to-head with the US Federal Trade Commission in the Supreme Court; the Court found that so-called pay-for-delay deals, which delay cheaper, generic forms of pharmaceuticals from being sold, can be subject to antitrust lawsuits.
Featured News
Crypto Regulation Measure Advances in the House
Jun 11, 2025 by
CPI
Shutterstock Shareholders Greenlight Merger with Getty Images
Jun 11, 2025 by
CPI
Seattle Considers Ban on Rent-Setting Algorithms Amid Collusion Allegations
Jun 11, 2025 by
CPI
Karina Lubell to Join Brunswick Group as Partner in Washington, DC Office
Jun 11, 2025 by
CPI
Turkish Competition Watchdog Launches Probe into Coca-Cola
Jun 11, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Industrial Policy
May 21, 2025 by
CPI
Industrial Strategy and the Role of Competition – Taking a Business Lens
May 21, 2025 by
Marcus Bokkerink
Industrial Policy, Antitrust, and Economic Growth: Some Observations
May 21, 2025 by
David S. Evans
Bolder by Design: Crafting Pro-Competitive Industrial Policies For Complex Challenges
May 21, 2025 by
Antonio Capobianco & Beatriz Marques
Competition-Friendly Industrial Policy
May 21, 2025 by
Philippe Aghion, Mathias Dewatripont & Patrick Legros